Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Preface W.S. FRED WONG 1. Genomic and non-genomic effects of glucocorticoids in respiratory diseases Zhao-Yong Lee and Thai Tran 2. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment Garry M. Walsh 3. Phosphodiesterase inhibitors and lung diseases Ivana Stolfa and Clive Page 4. Prospects for macrolide therapy of asthma and COPD Michael J. Parnham, Virginia Norris, Jennifer A. Kricker, Thorarinn Gudjonsson, and Clive P. Page 5. Targeting the renin angiotensin system for respiratory diseases Phyllis X.L. Gan, W. Liao, Kira M. Linke, D. Meid, X.D. Wu, and W.S. Fred Wong 6. Progress in the development of kinase inhibitors for treating asthma and COPD Nathaniel McClean, Jeffery D. Hasday, and Paul Shapiro 7. Anti-fibrotic strategies and pulmonary fibrosis Avanka Gunatilaka, Stephanie Zhang, Wan Shun Daniel Tan, and Alastair G. Stewart 8. Novel treatments against airway inflammation in COPD based on drug repurposing Rui Chen, Yuting Cui, and Judith C.W. Mak 9. Senotherapy for lung diseases Peter J. Barnes 10. Delivery technology of inhaled therapy for asthma and COPD Michael Y.T. Chow, Harry W. Pan, and Jenny K.W. Lam
